GSA Capital Partners LLP Acquires 1,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN

GSA Capital Partners LLP increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,440 shares of the biopharmaceutical company’s stock after acquiring an additional 1,358 shares during the quarter. GSA Capital Partners LLP’s holdings in Regeneron Pharmaceuticals were worth $1,934,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in REGN. Brighton Jones LLC increased its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $226,000. MGO One Seven LLC raised its position in shares of Regeneron Pharmaceuticals by 28.1% in the 2nd quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 106 shares in the last quarter. Mutual Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 6.0% in the 2nd quarter. Mutual Advisors LLC now owns 888 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 50 shares in the last quarter. Finally, Private Trust Co. NA lifted its stake in shares of Regeneron Pharmaceuticals by 16.5% in the 2nd quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 27 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,636 shares of company stock valued at $2,862,920 over the last three months. Insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HSBC raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Evercore lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Oppenheimer restated an “outperform” rating and issued a $865.00 price objective (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $803.17 on Tuesday. The firm has a market cap of $84.91 billion, a P/E ratio of 19.33, a PEG ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $764.16 and a 200 day moving average of $668.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $12.07 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.